Ahmed S. Abdelsamie

Ahmed S. Abdelsamie

Auto-generated profile, based on publicly available information

Ahmed S. Abdelsamie

ElexoPharm GmbH , Im Stadtwald, Building A1.2 , 66123 Saarbrücken , Germany

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2014 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SGShadia A. Galal
Shadia A. Galal
SKSarah H.M. Khairat
Sarah H.M. Khairat
FRFatma A.F. Ragab
Fatma A.F. Ragab
AAAhmed S. Abdelsamie
Ahmed S. Abdelsamie
MHMamdouh Moawad Ali Hassan
Mamdouh Moawad Ali Hassan
HDHoda I. El Diwani
Hoda I. El Diwani

1 January 2011 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SGShadia A. Galal
Shadia A. Galal
AAAhmed S. Abdelsamie
Ahmed S. Abdelsamie
HTHarukuni Tokuda
Harukuni Tokuda
NSNobutaka Suzuki
Nobutaka Suzuki
ALAkira Lida
Akira Lida
HDHoda I. El Diwani
Hoda I. El Diwani

1 November 2013 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SGShadia A. Galal
Shadia A. Galal
AAAhmed S. Abdelsamie
Ahmed S. Abdelsamie
SSSalwa M. Soliman
Salwa M. Soliman
JMJérémie Mortier
Jérémie Mortier
GWGerhard Wolber
Gerhard Wolber
HDHoda I. El Diwani
Hoda I. El Diwani

1 July 2017 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SGShadia A. Galal
Shadia A. Galal
AAAhmed S. Abdelsamie
Ahmed S. Abdelsamie
SSsamia shouman
samia shouman
YAYasmin M. Attia
Yasmin M. Attia
HAHamed I. Ali
Hamed I. Ali
HEHoda I. El-Diwani
Hoda I. El-Diwani

27 October 2023 in ACS Central Science
Verified
Journal Article
Open access
JKJelena Konstantinović
Jelena Konstantinović
AKAndreas Martin Kany
Andreas Martin Kany
AAAlaa Alhayek
Alaa Alhayek
AAAhmed S. Abdelsamie
Ahmed S. Abdelsamie
ASAsfandyar Sikandar
Asfandyar Sikandar
AHAnna Hirsch
Anna Hirsch
Infections caused by the Gram-negative pathogen Pseudomonas aeruginosa are emerging worldwide as a major threat to human health. Conventional antibiotic monotherapy suffers from rapid resistance development, underlining urgent need for novel treatment concepts. Here, we report on a nontraditional approach to combat P. aeruginosa-derived infections by targeting its main virulence factor, the elastase LasB. We discovered a new chemical class of phosphonates with an outstanding in vitro ADMET and PK profile, auspicious activity both in vitro and in vivo. We established the mode of action through a cocrystal structure of our lead compound with LasB and in several in vitro and ex vivo models. The proof of concept of a combination of our pathoblocker with levofloxacin in a murine neutropenic lung infection model and the reduction of LasB protein levels in blood as a proof of target engagement demonstrate the great potential for use as an adjunctive treatment of lung infections in humans.

1 June 2019 in Molecular and Cellular Endocrinology
Verified
Journal Article
Open access
MSMohamed Salah
Mohamed Salah
AAAhmed S. Abdelsamie
Ahmed S. Abdelsamie
MFMartin Frotscher
Martin Frotscher
During the past 25 years, the modulation of estrogen action by inhibition of 17β-hydroxysteroid dehydrogenase types 1 and 2 (17β-HSD1 and 17β-HSD2), respectively, has been pursued intensively. In the search for novel treatment options for estrogen-dependent diseases (EDD) and in order to explore estrogenic signaling pathways, a large number of steroidal and nonsteroidal inhibitors of these enzymes has been described in the literature. The present review gives a survey on the development of inhibitor classes as well as the structural formulas and biological properties of their most interesting representatives. In addition, rationally designed dual inhibitors of both 17β-HSD1 and steroid sulfatase (STS) as well as the first inhibitors of 17β-HSD14 are covered.